vs
Side-by-side financial comparison of BIODESIX INC (BDSX) and Celcuity Inc. (CELC). Click either name above to swap in a different company.
Biodesix Inc is a molecular diagnostics enterprise specializing in developing and commercializing innovative blood-based testing solutions for oncology and infectious disease fields. It primarily serves healthcare providers, biopharmaceutical partners and patients across North America, with core business covering personalized medicine products that support clinical decision making.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.8M | — | ||
| Q3 25 | $21.8M | — | ||
| Q2 25 | $20.0M | — | ||
| Q1 25 | $18.0M | — | ||
| Q4 24 | $20.4M | — | ||
| Q3 24 | $18.2M | — | ||
| Q2 24 | $17.9M | — | ||
| Q1 24 | $14.8M | — |
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-8.7M | — | ||
| Q2 25 | $-11.5M | — | ||
| Q1 25 | $-11.1M | — | ||
| Q4 24 | $-8.3M | — | ||
| Q3 24 | $-10.3M | — | ||
| Q2 24 | $-10.8M | — | ||
| Q1 24 | $-13.6M | — |
| Q4 25 | -6.8% | — | ||
| Q3 25 | -32.4% | — | ||
| Q2 25 | -48.6% | — | ||
| Q1 25 | -50.9% | — | ||
| Q4 24 | -32.5% | — | ||
| Q3 24 | -47.3% | — | ||
| Q2 24 | -46.0% | — | ||
| Q1 24 | -74.4% | — |
| Q4 25 | -13.8% | — | ||
| Q3 25 | -40.0% | — | ||
| Q2 25 | -57.3% | — | ||
| Q1 25 | -61.8% | — | ||
| Q4 24 | -40.4% | — | ||
| Q3 24 | -56.5% | — | ||
| Q2 24 | -60.3% | — | ||
| Q1 24 | -91.9% | — |
| Q4 25 | $-3.35 | — | ||
| Q3 25 | $-1.16 | — | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $-5.02 | — | ||
| Q3 24 | $-1.40 | — | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.14 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
